• The Happy Co. has unveiled Tropical Twist, a cool and refreshing addition to its PerX energy drink line
• PerX beverages are formulated to provide natural appetite control while boosting metabolism and energy
• The company also launched Probio8, a new probiotic dietary supplement product

Sharing Services Global’s (OTCQB: SHRG) wholly owned subsidiary, The Happy Co., has recently added to its exclusive product line. The company unveiled a new limited-time seasonal flavor for its popular energy drink PerX (https://ibn.fm/F3Lzz) and also launched a new probiotic dietary supplement product called Probio8 (https://ibn.fm/D6mqR). The Happy Co. is a leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness.

Called Tropical Twist, the new PerX product is a cool and refreshing energy drink designed to be “your neXt-level nootropic beverage.” The Happy Co. initially announced its PerX brand in January 2023, and since then the energy drink has become one of the most popular choices in the company’s product offerings. Featuring a proprietary nootropic formulation, the beverage is designed to provide natural appetite control while boosting metabolism and energy. Tropical Twist is the third flavor for the PerX brand; this limited-time release follows Frost, a previous limited release, and will be available along with PerX’s Berry Blast.

“The launch of this new flavor comes at the perfect time,” said Sharing Services CEO John “JT” Thatch. “PerX has already become a big favorite among our customers, and this new flavor is a fantastic way to give them something exciting for summer as well as being a great way for our brand partners to introduce new customers to this incredible product. We’re extremely pleased with how PerX has performed so far. By introducing new flavors in this limited-release format, we have the opportunity to continually expand this product category by learning what works directly from our customer base.”

In addition to its Tropic Twist announcement, SHRG’s The Happy Co. has launched a new probiotic dietary supplement product: Probio8. This gluten-free, sugar-free and vegan capsule offering contains eight different strains of beneficial probiotics, prebiotics and postbiotics, with each daily dose containing up to 23 billion healthy bacteria.

“The pursuit of exceptional health is central to everything we do here,” said Thatch. “We know that gut health is foundational to overall wellness, so developing a product as powerful as Probio8 means our customers have the greatest possible advantage when it comes to achieving their personal health goals.

“We’ve never been content to rest on the success of our existing products alone,” Thatch continued. “We’re committed to always expanding and improving what we do. Probio8 is a great example of how, even with our best products, we’re always looking for opportunities to innovate and to serve our customers better.”

Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer.

For more information and to see the full range of solutions offered by SHRG, visit the company’s website at www.SHRGInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers
• The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda
• The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets
• The granted patents, three Fast Track Designations, and positive preclinical and clinical data are poised to help the company accelerate its clinical development of REQORSA in its various development programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China – Genprex China Patent No: 201780076886.X – from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company’s drug candidate REQORSAI immunogene therapy in combination with PD-1 antibodies, such as KeytrI(R), to treat cancers (https://ibn.fm/AD3iX).

The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed after treatment with Keytruda. The first patient was dosed in this study in April of last year (https://ibn.fm/7lqLl).

Against the backdrop of the ongoing study, Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex, described how the patent granted in China provides Genprex with important additional protection for the use of the REQORSA and PD-1 antibody combination.

“Now with the latest patent grant in China, we have secured exclusivity for the use of this drug combination for the treatment of cancer in some of the most important markets in the world.  The company already has received patent protection in the U.S., Australia, Mexico, Japan and Russia.  This patent protection prevents others from using this drug combination to treat cancer in these jurisdictions,” Gallagher explains.

REQORSA uses the company’s non-viral ONCOPREX(R) Nanoparticle Delivery System, a systemic gene therapy platform for cancer. The system encapsulates within lipid nanoparticles a plasmid that expresses the TUSC2 tumor suppressor gene, creating the REQORSA drug product. The company then intravenously administers the encapsulated plasmid, which is then taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in these cells (https://ibn.fm/I80mh).

According to the company, “REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death (apoptosis) in cancer cells, and modulates the immune response against cancer cells.” This lead product candidate is initially being developed in combination with prominent cancer drugs Tagrisso(R), Keytruda(R), and Tecentriq(R) to treat NSCLC and small cell lung cancer (“SCLC”) (https://ibn.fm/gf7tO).

Having received three separate Fast Track Designations from the U.S. Food and Drug Administration (“FDA”) for its combination therapies with Tagrisso, Keytruda and Tecentriq, the company looks forward to accelerating the clinical development of REQORSA and potentially providing new treatments for patients. Moreover, Genprex’s growing patent portfolio is expected to boost these clinical development efforts.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches
• The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is expected to grow to $11.91 billion by 2029, driven by the growing ban on e-cigarettes worldwide
• The white pouch category is one of the fastest-growing, tobacco-free alternatives to smoking and vaping – growing at a CAGR of 13.4%

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that the United States Patent and Trademark Office (“USPTO”) has granted a strategically important new patent in the oral nicotine sector for its patented DehydraTECH(TM) technology. The granting of the new patent further substantiates the superior DehydraTECH processing and sublingual compositions through exceptional scientific study results and recognition by the USPTO (https://ibn.fm/862eh).

Lexaria’s new patent, US patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine, includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. DehydraTECH-nicotine has shown in multiple sets of animal testing that it can be delivered to the bloodstream up to 10-times to 20-times faster at up to 10-fold higher levels of nicotine into blood plasma from oral absorption than concentration-matched controls. The speed of onset has proven vital to nicotine users.

The oral nicotine pouch category interests Lexaria and the nicotine products industry, growing partly because of its reduced risk of health outcomes, as the US Food and Drug Administration has previously noted. The white pouch delivery method specifically avoids harmful lung outcomes experienced by smokers or vapers. It involves absorption primarily through the buccal and sublingual tissues of the mouth of purified nicotine that has been separated from the harmful substances found in most other formats.

The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is growing at a CAGR of 13.4% (https://ibn.fm/JhQ04). By 2029, the market is expected to reach $11.91 billion – driven by multiple countries banning the sale of e-cigarettes, the devices used in vaping. Currently, 37 countries have banned these devices, representing a cumulative population of over 2.3 billion people (https://ibn.fm/aX9Cj). The initial purpose of vaping was to help wean people off cigarette use, but it has become controversial and is limited in certain countries, with many restrictions and bans worldwide.

The US-granted patent is also progressing as a patent application through other jurisdictions internationally. The US patent and international patent applications are partly supported by the superior pharmacokinetic blood plasma data from Lexaria in its animal studies conducted from 2017 through 2021. This new patent builds nicely upon the company’s growing patent portfolio in the oral nicotine delivery sector, including the white pouch category for sublingual and buccal tissue delivery. The patents are built on a foundation of nicotine-specific patent filings dating back to 2019 and DehydraTECH patents dating back to 2016.

Lexaria’s DehydraTECH-nicotine has patents granted for oral nicotine delivery in the US, Canada, Australia, and is pending in numerous other countries. The white pouch category is one of the fastest growing, tobacco-free alternatives to smoking and vaping – emitting no smoke, odors, or vapors that can affect nearby persons and are a superior nicotine delivery method. Lexaria demonstrates this through its granted patents, subsequent studies, and future endeavors for sublingual and buccal delivery with DehydraTECH.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The FMCSA (Federal Motor Carrier Safety Administration) proposed a rule mandating speed limiters for most commercial vehicles
• The ATA has supported the move, while OOIDA (Owner Operator Independent Drivers Association) has opposed it, terming it as an attempt to eliminate one of the few advantages they enjoy over big business
• The FMCSA is yet to communicate its decision on the matter, pending its review of over 15,000 comments on the issue

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, is closely monitoring the developing situation with speed limiter directives on commercial vehicles. As a company heavily invested in the industry, such a directive could impact its performance and service delivery.

The Federal Motor Carrier Safety Administration (“FMCSA”) proposed a rule that would mandate speed limiters for most commercial vehicles. While the exact speed has not been confirmed, safety groups have proposed a 60 mph limit for heavy-duty trucks. This is not the first time such a proposal has been brought forth. Back in the Obama administration, a similar suggestion was made, ultimately facing opposition from the American Trucking Association (“ATA”) (https://ibn.fm/P8pMY).

The latest development has seen ATA rescind its stand in 2016, mainly on the basis that “Safety is a winning issue, and ATA enjoys winning.”  To this end, the association supports the rule requiring tamper-proof devices limiting Class 7 and 8 trucks to a fixed maximum of 65 mph, or 70 mph, with adaptive cruise control and automatic emergency braking. This, its management notes, is in response to new emerging data and technologies forcing the industry to adapt.

The Owner-Operator Independent Drivers Association (“OOIDA”) has opposed the proposition, terming it as a motive to eliminate one of the few advantages they enjoy over big businesses. For one, a survey conducted by the OOIDA Foundation in 2022 showed that only 10% of owner-operators had their trucks equipped with automatic emergency braking, while only 20% had adaptive cruise control. In comparison, large fleets, represented by ATA, already have installed speed limiters, mainly for liability and fuel efficiency reasons. In addition, these fleets are also more likely to have adaptive cruise control technology equipped, which alienates owner-operators (https://ibn.fm/Bdwqi).

The FMCSA has yet to communicate its decision on the matter, pending its review of over 15,000 comments. The ruling is projected to come in late summer or early fall, but FRGT is keeping a close eye on the matter and monitoring its development.

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• Global ambitions to achieve net zero status will necessitate a near tripling in annual clean energy investment
• Silver has emerged as a critical component of clean energy infrastructure due to its exceptional electric and thermal conductivity
• Nevertheless, a decrease in global silver production coupled with rising demand has left the precious metal in deficit – with the market undersupplied by nearly 238mn tonnes in 2022
• Eloro Resources’ Iska Iska deposit may be poised to emerge as a rare greenfield silver project with the company set to publish its inaugural NI 43-101 compliant mineral resource estimate

Global warming has become an undeniable force around the globe, with news of widespread droughts, record temperatures, forest fires, and ravaged agricultural harvests increasing in frequency. In response, global leaders came together during 2021’s COP26 event in Glasgow to propose a global Net Zero initiative, aimed towards achieving a balance between global greenhouse gas (“GHG”) emissions and those being removed from the atmosphere. Whilst a number of countries have since published their own legislation, detailing the measures and timeframes through which they expect to achieve a net zero status, there is a common consensus amongst all – the change will not be easy. Forecasts by the International Energy Agency now suggest that to reach global net zero emissions by 2050, annual clean energy investment around the globe will need to more than triple to approximately $4 trillion per annum by 2030.

The shift away from fossil fuels and towards renewable energy sources is resulting in a spending surge that is set to directly benefit businesses entrenched within the global renewable energy supply chain; in particular, commodities such as silver – a critical component within green energy technologies – are poised to witness a dramatic uptick in demand.

The average electric vehicle (“EV”) today contains anywhere between 25 and 50 grams of silver depending on the model, with hybrid cars using between 18 to 34 grams of silver. The precious metal’s electric and thermal properties combine to make silver an increasingly crucial constituent within electric vehicle batteries; today, the automotive sector uses 55 million ounces of silver annually, with demand anticipated to swell to as much as 90 million ounces by 2025 (https://ibn.fm/d1Z1I). Coupled with growing demand from solar panel manufacturers – a solar panel measuring approximately 2 square meters can use up to 20 grams of silver – the global silver market has now operated at a net deficit dating back to early 2021.

Global demand for silver rocketed by 18% last year to a record high of 1.24 billion ounces, resulting in a significant supply deficit, according to the Silver Institute (https://ibn.fm/pc6fv). The silver market was undersupplied by 237.7 million ounces in 2022, the institute said in its latest World Silver Survey, calling this “possibly the most significant deficit on record”.

“As demand associated with the electrification of the global economy grows, in order to fight climate change, it looks like the world will face persistent primary silver deficits over the long term. Silver uptake by the emerging EVs industry, smart devices, electrical grids, solar power generation and the conventional industrial products looks set to outpace the quantities produced by miners and recyclers,” explained Bart Melek, Head of Commodity Strategy at TD Securities. “If deficits persist for a prolonged period as expected, the inventory of above-ground stocks will diminish to levels which will be too low to consistently provide the buffer against deficits. This implies very high prices, as the silver sector will operate above the conventional supply curve.”

Although an approximate 1.3 billion oz in silver inventories may help stopgap the ongoing supply shortfall, the need for new, longer-term supplies of mined silver is gaining increased urgency. With its sights set on developing its promising Iska Iska project, Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has emerged as one of the key potential beneficiaries from the global boom in silver demand.

Nestled in the foothills of Bolivia’s Cerro Rico de Potosi, Eloro Resources’ Iska Iska deposit is situated deep within a region renowned for its prolific silver deposits. Despite accounting for nearly 80% of the world’s silver supply between the 16th and 18th centuries, the Potosi region was recently estimated to hold a world-class silver and tin reserve amounting to over 500 million tonnes grading ~100g/t Ag and 0.2 Sn.

Silver prices to date have not fully reflected the underlying supply-demand imbalance affecting the precious metal – with a combination of rising interest rates, inflationary pressures, and a deteriorating global macroeconomic environment weighing on investor sentiment. Nevertheless, growing expectations of a ‘dovish’ monetary policy tilt by the FOMC, alongside prospects of a ‘soft’-landing in the United States have led to rising longer-term price forecasts for the commodity.

 “As it becomes clear that the Fed and other central banks will start to pivot to a more dovish monetary policy stance in the early months of 2024, boosting the prospects for an economic recovery on the horizon, we expect the white metal will set its sights towards $26/oz in the final days 2023,” commented TD Securities’ Melek.

Eloro Resources’ initial exploratory drilling work within the Iska Iska deposit thus far has revealed the existence of a “magnificent core, which is remarkably consistent, continuous, and high grade at 90g/t silver equivalent and greater”. With Eloro on track to publish its inaugural NI 43-101 compliant mineral resource estimate (“MRE”) in the coming months, it may be fair to presume that Bolivia’s rich veins of silver may begin flowing again in the not-too-distant future.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

DGE invites life science Diversity, Equity & Inclusion (“DEI”) practitioners, health equity advocates, HR executives, and health policy leaders, to attend the 3rd Advancing Diversity, Equity & Inclusion in Pharma & Healthcare Summit to be held at the Hyatt Bellevue, Philadelphia, PA, on September 19-20, 2023. The industry’s leading event will focus on putting developing policies into practices including novel case studies and sessions on important areas.

The leading DEI event for Pharma & Healthcare serves as a dynamic platform for industry leaders, advocates, practitioners and influencers to convene, work toward common goals and drive the life science ecosystem toward positive change. Attendees will get the unique opportunity to meet with like-minded professionals, benchmark with peers and engage in thought-provoking discussions in the pursuit of an equitable and more inclusive future for all.

Featuring an exceptional blend of collaborative sessions, insightful presentations, and actionable strategies, this groundbreaking summit will leave an unforgettable mark on participants. They will engage in valuable panel discussions and gain information from keynote speakers who will share their unique strategies and experiences.

Advancing Diversity, Equity, and Inclusion

The summit will focus on the growing prominence of diversity and inclusion in clinical research and drug development. Expert-led sessions will explore the diverse patient populations in clinical trials while addressing differences in healthcare results.

Attendees will gain valuable insights into the challenges faced in implementing an effective DEI practice from the ground up as well as gathering cross-functional insights on DEI collaboration and the role of medical communications to address health inequities and disparities. In addition, the agenda will cover integrating DEI into talent recruitment, transforming organizational culture and utilizing change management. The event will also offer new case studies from Pfizer, Merck, Sanofi, Takeda and others. Formats will also include panel discussions such as the power of mentorship and ERGs.

The agenda will delve into the importance of actionable workplace culture that supports equity and inclusivity at all levels. The professionals from the pharma and healthcare industries will bring together different perspectives and strategies for improving DEI in the workplace as well as throughout the entire life science ecosystem most importantly with patients. The main focus will be to create industry-wide best practices and solutions that drive meaningful change throughout the industry that is viewed as a leader in diversity, equity and inclusion.

To learn more, please visit https://ibn.fm/S7hSF.

• BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price
• The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market
• DICE Therapeutics is currently evaluating its lead drug candidate, DC-806, an oral IL-17 inhibitor, in a Phase II trial, with early-stage results from the Phase I study showing a near-44% reduction in Psoriasis Area and Severity Index
• The report noted that the deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive with positive early-stage clinical results
• Also, revenues from FDA-approved psoriasis drugs show the potential value of the company should its IL-17 NanoAb therapy eventually receive FDA approval

According to Goldman Sachs Research, the global pharmaceutical industry is sitting on about $700 billion in dealmaking firepower, expected to fuel M&A-driven growth as companies look to revamp their intellectual property portfolio as their existing patents expire (https://ibn.fm/7VNq6). Flush with cash, big drugmakers also have easy access to alternative financing, factors that allow them to make aggressive acquisition bids for promising biotechnology companies and other targets (https://ibn.fm/Uo69R).

This played out recently when Eli Lilly and Company (NYSE: LLY) announced it had signed a definitive agreement with DICE Therapeutics, Inc. (NASDAQ: DICE) to acquire DICE (https://ibn.fm/CPCbR) in a deal valued at approximately $2.4 billion. DICE is a biopharmaceutical company that develops novel oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in clinical development to treat chronic immune system diseases.

The pending acquisition formed the basis of analysis by Aegis Capital Corp., which underlined that the recent M&A activity shows the potential value of BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products. Aegis, therefore, reiterated its Buy recommendation and a $70 target price on BiondVax (https://ibn.fm/wHmf2).

Aegis’ coverage followed BVXV’s June announcement that it had signed an exclusive worldwide license with the Max Planck Society and University Medical Center Göttingen (“UMG”), both in Germany, to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for all potential indications, starting with psoriasis and psoriatic arthritis (https://ibn.fm/5bpWM).

“The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases, but also another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” BiondVax CEO Amir Reichman said at the time. 

IL-17 is a family of immune system cytokines that comprises six isoforms (IL-17A to IL-17F). And while the IL-17 pathway is known to contribute to defenses against extracellular bacteria and fungi, it also plays a significant role in originating and feed-forwarding the inflammatory cycle of psoriasis (https://ibn.fm/I1Vqe). Psoriasis is a chronic autoimmune disease that causes inflammation and scaling of the skin. According to the National Psoriasis Foundation, about 8 million people in the U.S. and 125 million worldwide suffer from the condition (https://ibn.fm/sU999).

Given the causative role of IL-17, IL-17 inhibitors, most of which belong to a family of biological drugs called monoclonal antibodies (“mAbs”), are used to treat psoriasis. Chemically, these mAbs bind to the IL-17A cytokine, inhibiting interaction with the IL-17A receptor. However, “the latest and most effective mAbs for the treatment of plaque psoriasis that are currently marketed, as well as those that, to BiondVax’s knowledge, are under clinical development by other companies, target not only IL-17A but also IL-17F and IL-17A/F complex,” wrote the company in the June press release.

DICE’s lead drug candidate, DC-806, which is currently being evaluated in a Phase II study involving participants with moderate to severe plaque psoriasis, targets the IL-17A (https://ibn.fm/V70Fo). Early-stage results released last October nonetheless showed that the drug candidate led to a mean percentage reduction in Psoriasis Area and Severity Index (“PASI”) of up to about 44% compared to 13.3% for placebo. BiondVax’s NanoAbs exhibit several ‘biobetter’ qualities compared to mAbs and IL-17 inhibitors like DC-806, including better patient safety and convenience.

Little wonder that Aegis noted in its report, “This deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive if it has positive early-stage clinical results.” So far, several factors tip the scale in BiondVax’s favor. First, the company is focusing on a condition for which the mechanism of action of existing antibody-based treatments is well understood and has, in fact, been validated through clinical trials that have resulted in FDA approval. Secondly, a preclinical in vivo proof-of-concept study evaluating the company’s anti-COVID-19 NanoAb therapy virtually eliminated the virus from the lungs, caused milder and shorter illness, and had prophylactic properties. While the study evaluated an anti-COVID-19 drug, it showed, at least early on, the capabilities of NanoAbs.

Furthermore, should BiondVax eventually receive FDA approval for its anti-IL-17 NanoAbs, precedent exists showing that the company and its shareholders stand to gain significantly from the potential market demand. Of the three IL-17 inhibitors currently approved by the FDA, Cosentyx (secukinumab) by Novartis Pharmaceuticals Corp. delivered $4.8 billion in sales in 2022, up 5% year over year (https://ibn.fm/TBPVP), while Taltz (ixekizumab) by Eli Lilly generated $2.482 billion in 2022, up from $2.213 billion in 2021 (https://ibn.fm/nHncH). (Sales data from the third drug, Saliq (brodalumab) by Bausch Health, are not publicly available.)

Even with the enormous potential of BiondVax’s anti-IL-17 NanoAbs, the company is committed to developing a pipeline of diversified and commercially viable products and platforms, providing broad based and diversified opportunities for success. In addition to psoriasis and psoriatic arthritis, the company is targeting treatments of diseases with unmet medical needs and attractive commercial opportunities, including asthma, macular degeneration, and COVID-19.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats
• This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide
• The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits
• Lexaria is also actively seeking commercial partners during 2023 and 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them to make strides in the potential treatment of conditions such as hypertension, epilepsy, human hormone delivery, and nicotine replacement; all made possible through its patented technology, DehydraTECH(TM).

DehydraTECH enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats. The technology serves as an additional step that can be easily incorporated into any formulation and manufacturing process, allowing for speedy delivery, an increase in bioavailability, and an increase in brain absorption, among other advantages (https://ibn.fm/Cr9r8).

Lexaria’s studies have demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,700 percent, which has opened the technology up to new possibilities for improved drug delivery.

One stand-out feature of DehydraTECH is its ability to work symbiotically with existing physiological systems to enable masking oral and olfactory receptors, rendering DehydraTECH-processed compounds mostly flavorless and odorless. This results in formulations not requiring sweeteners or chemical masking agents for flavor and odor blocking, meaning that manufacturers can create low-sugar products with fewer calories while avoiding excessive artificial sweeteners.

Once ingested, the compounds, through the help of fatty acids, permeate the intestinal wall for the active payload, then are transported to the systemic circulation by one of two pathways, typically dependent on the type of fatty acid(s) chosen for a given formulation. For hepatic transport, or where liver metabolism is desirable for biotransformation of the payload, Lexaria’s methodology uses medium-chain fatty acids. For lymphatic transport, on the other hand, Lexaria uses long-chain fatty acids, which are absorbed via the lymphatic lacteals, ultimately diverting them away from the liver and entering the general circulation very quickly.

DehydraTECH and its unique approach to drug delivery have earned Lexaria a current total of 35 patents across the United States, Canada, Mexico, Australia, Japan, India, and the European Union. Although it has already achieved considerable intellectual property protection through its existing patent portfolio, the company has a number of additional patents pending worldwide. These achievements have sparked interest across various industries. Lexaria’s CEO, Chris Bunka, has noted the company’s active discussions with multi-billion dollar companies for the potential use of its technology in their commercial product pursuits.

“Our applied R&D is paying off in spades because we are currently in active discussions with several multi-billion dollar companies around the world for the potential use of Lexaria’s DehydraTECH technology in their commercial product pursuits,” noted Mr. Bunka.

“These discussions are ongoing and have thus helped us to meet one of our primary objectives of the last year, which is to introduce DehydraTECH to world-leading potential collaborators,” he added (https://ibn.fm/l2zam).

Lexaria is ambitious in its push for DehydraTECH and is currently seeking commercial partners to use the technology in what are usually multi-billion-dollar markets. The company is taking steps to have multiple choices in how to fund its operations, and so far, it is on track to have 2023 as its best year ever.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• D-Wave is working with a portfolio of impressive commercial customers including Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, and many more
• Governments worldwide are calling for the implementation of quantum applications – with the United States pushing for development and deployment of quantum applications within the next 24 months
• D-Wave, the world’s first commercial quantum computing solutions supplier, is successfully filling the increasing quantum needs of customers along with the growing interest of the government for expanding quantum technology

D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, continues to provide customers clear value via practical quantum and quantum-hybrid applications that solve real-world problems in the areas of logistics, artificial intelligence, materials sciences, drug discovery, scheduling, and financial modeling. The company delivers these applications to a portfolio of blue-chip industry leaders that include Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, and more – reflecting the growing interest and adoption of today’s quantum annealing technology among forward-looking companies.

D-Wave’s quantum technology has been applied to a multitude of computationally complex problems, from grocery store optimization to protein design. Groovenauts and Mitsubishi Estate utilized quantum annealing to optimize waste collection and reduce carbon dioxide emissions by 57% (https://ibn.fm/vxRnH). Pattison Food Group reduced the time of important grocery optimization tasks from 25 hours to two minutes using D-Wave’s quantum technology (https://ibn.fm/9HH8Y). Sigma-i streamlined personnel management through quantum computing (https://ibn.fm/oWbjp).

As awareness of quantum annealing’s value to the enterprise grows, D-Wave is also providing resources to streamline adoption. It designed the Launch™ program to help enterprises accelerate the quantum journey by facilitating the transition from problem discovery to production implementation. The company’s in-house professional services teams and technical domain experts help customers start their first quantum project and drive application development through to real-world production implementation.

Various forward-thinking organizations see quantum as an opportunity to move ahead of the competition. According to Hyperion Research, 80% of early adopters plan to increase their commitment to quantum in the next two to three years (https://ibn.fm/RBgMA). Governments worldwide are also pushing for the implementation of quantum applications – with the United States pushing for development and deployment within the next 24 months.

D-Wave Quantum recently announced that it had regained listing compliance with the New York Stock Exchange (“NYSE”), meeting its continued listing standard for the minimum share price. On July 3, 2023, the NYSE provided D-Wave with a notification letter of recompliance based on the company’s minimum share price being at least $1.00 on June 30, 2023, and a calculation of the average closing price for 30 trading days that reflected the $1.00 minimum requirement on the applicable dates. D-Wave will continue to be traded on the NYSE, subject to all applicable listing standards (https://ibn.fm/MIFh2).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• Report projects that demand for nickel from the battery industry is set to increase significantly
• Texmont testing delivers results that meet or exceed expectations
• The company has acquired 403 additional mining claims within the Texmont ultramafic trend

With experts predicting that nickel metal will play a key role in the 2023 battery-grade market (https://ibn.fm/e8Ky4), Canada Nickel Company (TSX.V: CNC) (OTCQX: CNIKF) appears to be ideally positioned in the growing space. The company just released initial results from preliminary metallurgical testing at its Texmont Nickel Sulphide Project, and the results meet or exceed historical results (https://ibn.fm/NpwuL).

Nickel metal has a key role to play in 2023 battery grade market, states a recent Fastmarkets report. “With global lithium-ion battery production forecast to grow significantly in the coming years, market participants in the global nickel industry are working on the most efficient way to produce nickel sulfate for lithium-ion battery cathodes,” the article notes. “In addition, nickel sulfate is a key component in nickel-manganese-cobalt (“NMC”) units, and nickel-rich batteries are often preferred over lithium-ion batteries due to their high energy density and longer range when used in electric vehicles (“EVs”).

“Demand for nickel from the battery industry is, therefore, set to increase significantly,” the report continued. “Fastmarkets researchers forecast that demand for nickel for use in EV batteries represents around 280,000 tonnes per year of nickel metal globally, which corresponds to around 10% of worldwide demand for nickel. vBut this figure is set to grow significantly. Demand from the battery industry is expected to increase to close to 314,000 tonnes in 2023 and to 668,000 tonnes by 2025.”

With that projection as a backdrop, Canada Nickel’s report of nickel recoveries of 79% to 84% couldn’t have come at a better time. “Texmont continues to deliver excellent results, with initial metallurgy yielding nickel and cobalt recoveries and concentrate grades exceeding our expectations,” said Canada Nickel CEO Mark Selby. “Further, these results were achieved with a simple flowsheet, which will maximize potential opportunities to toll mill our initial production. I look forward to the next phases of work while we complete our initial resource on Texmont and complete a Preliminary Economic Analysis (‘PEA’) by year-end.”

Canada Nickel’s Texmont property is a past-producing mine that contains a large ultramafic body. The company has identified a near-surface, high-grade zone of less than 1% nickel wrapped within a moderate-high grade zone of 0.6 to 1.0% nickel, and Canada Nickel management is evaluating the potential for near-term production from Texmont through open pit mining of this moderate-high grade material. The company is planning to finalize the metallurgical flowsheet in the coming months, including conducting locked cycle and metallurgical variability tests. Following that, Canada Nickel anticipates releasing recovery equations for the Texmont PEA by the end of 2023.

In addition, the company announced that it has acquired 403 additional mining claims within the Texmont ultramafic trend through a series of purchase and sale agreements. “Given our success at Texmont, we capitalized on the opportunity to acquire regional mining claims, consolidating 20 kilometres of property with the potential to find more Texmont-style deposits,” Selby stated. “We have signed a total of 10 agreements, which consolidate 9,520 hectares of mining claims. We view this as an important and highly prospective addition to our Timmins Nickel District.”

Canada Nickel Company is advancing the next generation of nickel-sulphide projects to deliver nickel required to feed the high-growth electric vehicle and stainless-steel markets. Canada Nickel Company is pursuing the development of processes to allow the production of net zero carbon nickel, cobalt and iron products. The company provides investors with leverage to nickel in low political-risk jurisdictions. Canada Nickel is currently anchored by its wholly owned flagship Crawford Nickel-Cobalt Sulphide Project in the heart of the prolific Timmins-Cochrane mining camp.

For more information, visit the company’s website at www.CanadaNickel.com. 

NOTE TO INVESTORS: The latest news and updates relating to CNIKF are available in the company’s newsroom at https://ibn.fm/CNIKF